Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.02 EUR
Change Today 0.00 / 0.00%
Volume 0.0
EYJ On Other Exchanges
Symbol
Exchange
Berlin
OTC US
OTC US
As of 4:00 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

qrxpharma ltd (EYJ) Snapshot

Open
--
Previous Close
€0.02
Day High
--
Day Low
--
52 Week High
09/5/14 - €0.02
52 Week Low
03/18/15 - €0.0070
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
164.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QRXPHARMA LTD (EYJ)

Related News

No related news articles were found.

qrxpharma ltd (EYJ) Related Businessweek News

No Related Businessweek News Found

qrxpharma ltd (EYJ) Details

QRxPharma Limited develops and commercializes biopharmaceutical products primarily in Australia. It develops proprietary Dual Opioid formulations for treating patients with moderate to severe acute or chronic pain. The company develops pain management products consisting of Moxduo Immediate Release, an oral capsule for the treatment of moderate to severe acute pain; Moxduo Controlled Release oral tablet for chronic pain; and Moxduo Intravenous formulation for hospital-based, post-surgical pain, as well as Pro-drug/Hybrid Dual Opioids. It also offers abuse prevention products, including Stealth Beadlets abuse deterrent technology. QRxPharma Limited is based in North Sydney, Australia.

qrxpharma ltd (EYJ) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$441.2K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$262.8K
Senior Vice President of Global Business Deve...
Total Annual Compensation: A$326.6K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: A$65.1K
Compensation as of Fiscal Year 2014.

qrxpharma ltd (EYJ) Key Developments

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action against QRx Pharma, Ltd

Glancy Prongay & Murray LLP announced the filing of a class action lawsuit on behalf of investors of QRx Pharma Ltd., who purchased shares between January 24, 2011 and April 23, 2014, inclusive. QRX investors have until August 21, 2015 to file a motion to serve as lead plaintiff in the class action. The complaint alleges that QRx Pharma issued false and misleading public statements and omitted material facts concerning the commercial prospects for its experiment drug Moxduo. Specifically, the complaint alleges that QRx Pharma failed to disclose to investors that it received a "no agreement letter" from the Food and Drug Administration regarding its Moxduo trials and further misrepresented and concealed other material facts concerning its attempts to get Moxduo approved. Upon the disclosure of an FDA memo which denied QRx Pharma's application to get Moxduo approved, the price of QRx Pharma ADRs plummeted over 83% on April 23, 2014.

The Rosen Law Firm Files Class Action Lawsuit on Behalf of Purchasers of QRx Pharma, Ltd American Depository Shares

The Rosen Law Firm announced that the filing of a class action lawsuit on behalf of purchasers of QRx Pharma Ltd. American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the ‘class period’). The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws. According to the lawsuit, the company made false and/or misleading statements concerning the commercial prospects for its experimental drug Moxduo. Specifically, the company failed to disclose that it received a 'no agreement letter' from the FDA regarding its trials for Moxduo. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed.

QRxPharma Limited(ASX:QRX) dropped from S&P/ASX All Ordinaries Index

QRxPharma Limited(ASX:QRX) dropped from S&P/ASX All Ordinaries Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EYJ:GR €0.02 EUR 0.00

EYJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EYJ.
View Industry Companies
 

Industry Analysis

EYJ

Industry Average

Valuation EYJ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.8x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QRXPHARMA LTD, please visit www.qrxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.